These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 19805031)

  • 1. Toll-like receptor 2 dependent immunogenicity of glycoconjugate vaccines containing chemically derived zwitterionic polysaccharides.
    Gallorini S; Berti F; Mancuso G; Cozzi R; Tortoli M; Volpini G; Telford JL; Beninati C; Maione D; Wack A
    Proc Natl Acad Sci U S A; 2009 Oct; 106(41):17481-6. PubMed ID: 19805031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introduction of zwitterionic motifs into bacterial polysaccharides generates TLR2 agonists able to activate APCs.
    Gallorini S; Berti F; Parente P; Baronio R; Aprea S; D'Oro U; Pizza M; Telford JL; Wack A
    J Immunol; 2007 Dec; 179(12):8208-15. PubMed ID: 18056364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haemophilus influenzae type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human toll-like receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity.
    Latz E; Franko J; Golenbock DT; Schreiber JR
    J Immunol; 2004 Feb; 172(4):2431-8. PubMed ID: 14764714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the Effect of Conjugation Site and Chemistry on the Immunogenicity of an anti-Group B Streptococcus Glycoconjugate Vaccine Based on GBS67 Pilus Protein and Type V Polysaccharide.
    Nilo A; Passalacqua I; Fabbrini M; Allan M; Usera A; Carboni F; Brogioni B; Pezzicoli A; Cobb J; Romano MR; Margarit I; Hu QY; Berti F; Adamo R
    Bioconjug Chem; 2015 Aug; 26(8):1839-49. PubMed ID: 26230938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacterial polysaccharides with zwitterionic charge motifs: Toll-like receptor 2 agonists, T cell antigens, or both?
    Wack A; Gallorini S
    Immunopharmacol Immunotoxicol; 2008; 30(4):761-70. PubMed ID: 18686103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
    Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
    Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine.
    Paoletti LC; Wessels MR; Rodewald AK; Shroff AA; Jennings HJ; Kasper DL
    Infect Immun; 1994 Aug; 62(8):3236-43. PubMed ID: 8039893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycoconjugate vaccines: some observations on carrier and production methods.
    MacCalman TE; Phillips-Jones MK; Harding SE
    Biotechnol Genet Eng Rev; 2019 Oct; 35(2):93-125. PubMed ID: 32048549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
    Kasper DL; Paoletti LC; Wessels MR; Guttormsen HK; Carey VJ; Jennings HJ; Baker CJ
    J Clin Invest; 1996 Nov; 98(10):2308-14. PubMed ID: 8941648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Group B Streptococcus Glycan-Conjugate Vaccines Using Pilus Protein GBS80 As Carrier and Antigen: Comparing Lysine and Tyrosine-directed Conjugation.
    Nilo A; Morelli L; Passalacqua I; Brogioni B; Allan M; Carboni F; Pezzicoli A; Zerbini F; Maione D; Fabbrini M; Romano MR; Hu QY; Margarit I; Berti F; Adamo R
    ACS Chem Biol; 2015 Jul; 10(7):1737-46. PubMed ID: 25906283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carrier priming with CRM 197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: biophysical and immunochemical interpretation.
    Pecetta S; Lo Surdo P; Tontini M; Proietti D; Zambonelli C; Bottomley MJ; Biagini M; Berti F; Costantino P; Romano MR;
    Vaccine; 2015 Jan; 33(2):314-20. PubMed ID: 25448110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine.
    Goyette-Desjardins G; Calzas C; Shiao TC; Neubauer A; Kempker J; Roy R; Gottschalk M; Segura M
    Infect Immun; 2016 Jul; 84(7):2059-2075. PubMed ID: 27113360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Adjuvant That Increases Protective Antibody Responses to Polysaccharide Antigens and Enables Recall Responses.
    Phipps JP; Haas KM
    J Infect Dis; 2019 Jan; 219(2):323-334. PubMed ID: 30289460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zwitterionic polysaccharides stimulate T cells by MHC class II-dependent interactions.
    Kalka-Moll WM; Tzianabos AO; Bryant PW; Niemeyer M; Ploegh HL; Kasper DL
    J Immunol; 2002 Dec; 169(11):6149-53. PubMed ID: 12444118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.
    Baker CJ; Paoletti LC; Wessels MR; Guttormsen HK; Rench MA; Hickman ME; Kasper DL
    J Infect Dis; 1999 Jan; 179(1):142-50. PubMed ID: 9841833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational chemical design of the carbohydrate in a glycoconjugate vaccine enhances IgM-to-IgG switching.
    Guttormsen HK; Paoletti LC; Mansfield KG; Jachymek W; Jennings HJ; Kasper DL
    Proc Natl Acad Sci U S A; 2008 Apr; 105(15):5903-8. PubMed ID: 18378894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
    Wessels MR; Paoletti LC; Pinel J; Kasper DL
    J Infect Dis; 1995 Apr; 171(4):879-84. PubMed ID: 7706814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moderate PEGylation of the carrier protein improves the polysaccharide-specific immunogenicity of meningococcal group A polysaccharide conjugate vaccine.
    Zhang T; Yu W; Wang Y; Hu T
    Vaccine; 2015 Jun; 33(28):3208-14. PubMed ID: 25964170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein.
    Baraldo K; Mori E; Bartoloni A; Norelli F; Grandi G; Rappuoli R; Finco O; Del Giudice G
    Infect Immun; 2005 Sep; 73(9):5835-41. PubMed ID: 16113302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing a new antifungal glycoconjugate vaccine.
    Johnson MA; Bundle DR
    Chem Soc Rev; 2013 May; 42(10):4327-44. PubMed ID: 23232662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.